Microbiome: Hope or Hype

Although we have long known about the existence of microbes—the tiny bacteria, fungi and archaea that live all around us, on us, and in us—interest in how the microbiome might impact human therapeutics has become a hot topic in research only recently.

It is estimated that there are as many as 100 trillion bacteria in the human body. At that number, the human body and its microbiome live in a symbiotic relationship with each other, and it is speculated that one cannot live without the other.

Will future advances in deciphering this paradigm provide hope and revolutionize the healthcare industry of the future and help innovate new ways to control disease and human growth, or is this hype going to unlock a Pandora’s Box of issues, which we understand little about now?

This whitepaper addresses:

  • How will microbiome impact Human Therapeutics? Who’s driving it and why?
  • Is the real way to a person’s heart through their stomach? Maybe the ancients knew!
  • Financial approach and ROI for early and late stage investments into this arena
  • Timelines for impact in terms of developing therapeutics and diagnostics
  • Advances in the sciences needed to “really” understand what’s going on
  • Opportunities and challenges of delving into the human microbiome
  • Where is this field headed in terms of pharma and healthcare involvement?
  • What partnerships are critically needed between academia, companies, financial institutions and the government?
  • Predictions on translation of early successes to therapeutic area
  • FDA and the microbiome – friend or foe?
  • VIEW THE
    WHITEPAPER

    WHITEPAPER AUTHOR:

    Company team

    Ravi Kiron, PhD, MBA - Moderator

    Managing Partner, BioPharm Strategy Advisors Inc.

    Dr. Ravi Kiron is well versed in various aspects of the pharma and biotech R&D value chain across from early discovery and pre-clinical through late-stage clinical development, IP & regulatory strategy, product commercialization, technology & business development, marketing & launch – over the past 30 years. Read More

    Company team

    Mark S. Wilson, MBA - Panelist

    President and CEO, MatriSys Bioscience, Inc. 

    Mr. Wilson brings more than 29 years of life science entrepreneurship experience in biopharmaceutical development, business development, licensing, strategic alliance formation and management. Mr. Wilson is currently the Co-founder, President, and CEO of MatriSys Bioscience, Inc. a clinical stage skin microbiome company.  Read More

    Company team

    Colleen Cutcliffe, PhD - Panelist

    CEO and Co-Founder, Whole Biome

    Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome, Inc, which is developing novel microbiome interventions and diagnostics using a proprietary discovery platform. Colleen has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Whole Biome, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Read More

    Company team

    Mohan Iyer, MBA - Panelist

    Chief Business Officer, Second Genome

    Mohan S. Iyer is Chief Business Officer of Second Genome, one of the leading start-ups in the microbiome field.  He started his career as a biochemical engineer at Genentech in the mid-80s, when the biotech industry itself was comprised of start-ups.  In a career spanning almost 30 years in biotech, he has held various executive level positions in both technical and business functions at several start-ups in the San Francisco Bay Area.  Read More 

    Sponsored by: